unknown
Stage
1
Investors
About
Circular Genomics develops clinical biomarker tests based on circular RNA (circRNA) and associated bioinformatics to diagnose, monitor, and predict treatment response for psychiatric and neurological disorders. The company is building a pipeline of blood-based tests for precision psychiatry and neurology.
Explore Circular Genomics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.